Literature DB >> 9576084

Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion.

C A Mack1, C J Magovern, K T Budenbender, S R Patel, E A Schwarz, P Zanzonico, B Ferris, T Sanborn, P Isom, B Ferris, T Sanborn, O W Isom, R G Crystal, T K Rosengart.   

Abstract

PURPOSE: Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis, and transgene expression from adenovirus vectors can provide in vivo delivery of proteins. On the basis of this knowledge, we hypothesized that local administration of a replication-deficient adenovirus vector expressing complementary DNA for VEGF (AdVEGF) would induce collateral vessel formation in the setting of ischemia that could protect against subsequent acute vascular occlusion.
METHODS: Hindlimb ischemia was induced in Sprague-Dawley rats by means of unilateral ligation of the common iliac artery immediately followed by administration of 4 x 10(9)-plaque-forming units VEGF, the control vector AdNull, or phosphate-buffered saline solution into the iliofemoral adipose tissue and thigh muscles. Untreated rats with common iliac ligation were used as an additional control group.
RESULTS: Local VEGF expression was observed for 5 days in AdVEGF-treated rats but not in controls. Three weeks after ligation and vector administration, the ipsilateral femoral artery was ligated for a model of an acute vascular occlusion in the setting of preexisting ischemia. Blood flow to the ischemic hindlimb relative to the contralateral hindlimb evaluated with color microspheres demonstrated significantly increased blood flow in the AdVEGF-treated rats compared with each control group (p < 0.0001). Relative blood flow assessed by means of 99mTc-sestamibi radionuclide scans also demonstrated increased blood flow to the ligated hindlimb of AdVEGF-treated rats compared with each control group (p < 0.002). AdVEGF-treated rats also demonstrated increased vascularity in the ligated limb compared with each control group as assessed by means of angiography (p < 0.0001) and histologic quantification of blood vessels less than 80 microm diameter in local adipose tissue and capillaries per muscle fiber (p < 0.0002). AdVEGF treatment prevented a rise in femoral venous lactate femoral venous concentrations 1 hour after femoral artery ligation in control rats (p < 0.04).
CONCLUSIONS: An adenovirus vector expressing VEGF complementary DNA is capable of stimulating an angiogenic response that protects against acute vascular occlusion in the setting of preexisting ischemia, suggesting that in vivo gene transfer of VEGF complementary DNA might be useful in prophylaxis of advancing arterial occlusive disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576084     DOI: 10.1016/s0741-5214(98)70236-8

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

Review 1.  Growth factor delivery for oral and periodontal tissue engineering.

Authors:  Darnell Kaigler; Joni A Cirelli; William V Giannobile
Journal:  Expert Opin Drug Deliv       Date:  2006-09       Impact factor: 6.648

2.  A Prospective, Nonrandomized, no Placebo-Controlled, Phase I/II Clinical Trial Assessing the Safety and Efficacy of Intramuscular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Severe Buerger's Disease.

Authors:  Jeong Chan Ra; Euicheol C Jeong; Sung Keun Kang; Seog Ju Lee; Kyoung Ho Choi
Journal:  Cell Med       Date:  2016-10-03

3.  Viral vectors for vascular gene therapy.

Authors:  Lukas Fischer; Meir Preis; Anat Weisz; Belly Koren; Basil S Lewis; Moshe Y Flugelman
Journal:  Exp Clin Cardiol       Date:  2002

Review 4.  Adenovirus: the first effective in vivo gene delivery vector.

Authors:  Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-01       Impact factor: 5.695

Review 5.  Diabetes-associated macrovascular complications: cell-based therapy a new tool?

Authors:  Maddalena Gili; Alberto Orsello; Sara Gallo; Maria Felice Brizzi
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

6.  Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.

Authors:  B G Harvey; N R Hackett; T El-Sawy; T K Rosengart; E A Hirschowitz; M D Lieberman; M L Lesser; R G Crystal
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 7.  Current concepts of bone tissue engineering for craniofacial bone defect repair.

Authors:  Brian Alan Fishero; Nikita Kohli; Anusuya Das; John Jared Christophel; Quanjun Cui
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-11-18

8.  Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.

Authors:  T K Rosengart; L Y Lee; S R Patel; P D Kligfield; P M Okin; N R Hackett; O W Isom; R G Crystal
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

9.  Femoral artery occlusion augments TRPV1-mediated sympathetic responsiveness.

Authors:  Jihong Xing; Zhaohui Gao; Jian Lu; Lawrence I Sinoway; Jianhua Li
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

10.  Gene therapy using hepatocyte growth factor expressing adenovirus improves skin flap survival in a rat model.

Authors:  Dong Kyun Rah; In Sik Yun; Chae-Ok Yun; Sae Bin Lee; Won Jai Lee
Journal:  J Korean Med Sci       Date:  2014-11-21       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.